Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 1

Ciclesonide for the treatment of asthma

Authors Ronald Dahl

Published 15 March 2006 Volume 2006:2(1) Pages 25—37

Ronald Dahl

Professor of Respiratory Medicine and Allergology, Department of Respiratory Diseases & Allergy, Aarhus University Hospital, Arhus, Denmark

Abstract: Ciclesonide is a nonhalogenated corticosteroid that is converted to its clinicallyactive metabolite, desisobutyryl-ciclesonide, by esterases in the airways. Pharmacodynamic studies have shown that inhaled ciclesonide has potent antiinflammatory activity in patients with asthma, and does not appear to have clinically relevant systemic effects, even at high doses. It is highly protein-bound and rapidly metabolized by the liver, and thus has a low oral bioavailability. Ciclesonide is formulated as a solution for inhalation using a hydrofluoroalkane pressurized metered-dose inhaler. This formulation delivers a high fraction of respirable particles that yield high lung deposition with even distribution throughout the lungs and minimal oropharyngeal deposition. Results from numerous 12-week trials in patients (including children) with varying degrees of asthma show that morning or evening dosing with ciclesonide is more effective than placebo, and at least equivalent to other inhaled corticosteroids such as budesonide and fluticasone, with regard to improved spirometry, symptom scores, and less need for rescue medication. Results with once-daily ciclesonide are similar to those with twice-daily budesonide or fluticasone. At the dosages used in clinical trials, ciclesonide did not exert any untoward adverse effects and did not affect cortisol production. The favorable pharmacological properties of ciclesonide help explain the low incidence of adverse events, which are mostly mild to moderate in nature. Once-daily ciclesonide offers an efficacious treatment option for stepwise asthma management when inhaled corticosteroids are required.

 

Keywords: ciclesonide, asthma, inhaled corticosteroids, adults, children

Download Article [PDF] 

Readers of this article also read:

Free radical scavenging in vitro and biological activity of diphenyl diselenide-loaded nanocapsules: DPDS-NCS antioxidant and toxicological effects

Stefanello ST, Dobrachinski F, Carvalho NR, Amaral GP, Barcelos RP, Oliveira VA, Oliveira CS, Giordani CFA, Pereira ME, Rodrigues OED, Soares FAA

International Journal of Nanomedicine 2015, 10:5663-5670

Published Date: 4 September 2015

Clinical management and therapeutic outcome of infertile couples in southeast Nigeria

Menuba IE, Ugwu EO, Obi SN, Lawani LO, Onwuka CI

Therapeutics and Clinical Risk Management 2014, 10:763-768

Published Date: 1 October 2014

The impact of cardiac and noncardiac comorbidities on the short-term outcomes of patients hospitalized with acute myocardial infarction: a population-based perspective

Chen HY, Saczynski JS, McManus DD, Lessard D, Yarzebski J, Lapane KL, Gore JM, Goldberg RJ

Clinical Epidemiology 2013, 5:439-448

Published Date: 7 November 2013

Portal vein thrombosis in a patient with HCV cirrhosis and combined hemophilia A and thrombophilia V Leiden

Nikos Eleftheriadis, Pantelis Makris

Therapeutics and Clinical Risk Management 2010, 6:539-541

Published Date: 26 October 2010

Comparison of echinocandin antifungals

Gregory Eschenauer, Daryl D DePestel, Peggy L Carver

Therapeutics and Clinical Risk Management 2007, 3:71-97

Published Date: 15 March 2007

Etanercept in the treatment of rheumatoid arthritis

Boulos Haraoui, Vivian Bykerk

Therapeutics and Clinical Risk Management 2007, 3:99-105

Published Date: 15 March 2007

Acne phototherapy with a 1450-nm diode laser: an open study

Natusko Konishi, Hideki Endo, Naoki Oiso, Shigeru Kawara, Akira Kawada

Therapeutics and Clinical Risk Management 2007, 3:205-209

Published Date: 15 March 2007

Oxybutynin: an overview of the available formulations

Rebecca J McCrery, Rodney A Appell

Therapeutics and Clinical Risk Management 2006, 2:19-24

Published Date: 15 March 2006